Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights | Zendy

Tarfah AlWarhi | Zendy; Ahmed M. El Kerdawy | Zendy; Mohamed A. Said | Zendy; Amgad Albohy | Zendy; Zainab M. Elsayed | Zendy; Nada Aljaeed | Zendy; Eslam B. Elkaeed | Zendy; Wagdy M. Eldehna | Zendy; Hatem A. AbdelAziz | Zendy; Miral A. Abdelmoaz | Zendy

Open Access

Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights

Author(s) -

Tarfah AlWarhi,

Ahmed M. El Kerdawy,

Mohamed A. Said,

Amgad Albohy,

Zainab M. Elsayed,

Nada Aljaeed,

Eslam B. Elkaeed,

Wagdy M. Eldehna,

Hatem A. AbdelAziz,

Miral A. Abdelmoaz

Publication year - 2022

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s356988

Subject(s) - erlotinib , docking (animal) , apoptosis , ic50 , epidermal growth factor receptor , chemistry , a549 cell , cell culture , pyrazoline , cell growth , mtt assay , cytotoxic t cell , protein data bank (rcsb pdb) , cancer research , pharmacology , in vitro , stereochemistry , receptor , biology , biochemistry , medicine , nursing , organic chemistry , genetics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research